Search results
Results from the WOW.Com Content Network
Myostatin inhibitors are a class of drugs that work by blocking the effect of myostatin, which inhibits muscle growth. In animal models and limited human studies, myostatin inhibitors have increased muscle size. They are being developed to treat obesity, sarcopenia, muscular dystrophy, and other illnesses.
Myostatin inhibitors can improve athletic performance and therefore there is a concern these inhibitors might be abused in the field of sports. [51] However, studies in mice suggest that myostatin inhibition does not directly increase the strength of individual muscle fibers. [52]
Pages in category "Myostatin inhibitors" The following 7 pages are in this category, out of 7 total. This list may not reflect recent changes. A. Apitegromab; B.
Myostatin is a protein that inhibits the growth of muscle tissue, stamulumab is a recombinant human antibody designed to bind to and inhibit the activity of myostatin. [ 3 ] Stamulumab is a G1 immunoglobulin antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin ...
Apitegromab (SRK-015) is a fully human monoclonal antibody developed to treat spinal muscular atrophy.It works by binding to and inhibiting promyostatin, a precursor to myostatin, which limits the size of skeletal muscle tissue, as well as inactive myostatin.
Myostatin, a TGF-beta superfamily member, is a negative regulator of muscle growth. [1] Myostatin binds to ACVR2B and to a lesser extent ACVR2A. In mice that were ACVR2A −/− ( null ) mutants there was an increase in all four muscle groups studied ( pectoralis , triceps , quadriceps , and gastrocnemious / plantaris muscles). [ 1 ]
Follistatin is studied for its role in regulation of muscle growth in mice, as an antagonist to myostatin (also known as GDF-8, a TGF superfamily member) which inhibits excessive muscle growth. Lee and McPherron demonstrated that inhibition of GDF-8, either by genetic elimination ( knockout mice ) or by increasing the amount of follistatin ...
Bimagrumab, an experimental drug, works by inhibiting the action of myostatin, which limits the size of skeletal muscle. The drug has shown the ability to increase lean mass simultaneously to decreasing fat mass in obese humans, which is beneficial because it preserves or increases energy expenditure while reducing risks associated with excess fat.